Ryan Scott

First-line avelumab maintenance demonstrated efficacy and manageable toxicity in patients with low tumor burden advanced urothelial carcinoma.

During Sarcoma Awareness Month, Adam C. Berger, MD, FACS, discusses the importance of timely scans and recognizing the symptoms of sarcoma.

A panel of oncologists engage in a case-based discussion of patients with locally advanced disease at the 25th Annual International Lung Cancer Congress.

Sara M. Tolaney, MD, MPH, shares biopsy considerations when determining HER2-low status for patients with TNBC and details data within the TNBC landscape.

Sara M. Tolaney, MD, MPH, discusses the transformation of treatments for patients with triple-negative breast cancer.

Health Canada has granted full approval to dostarlimab monotherapy for patients with recurrent or advanced dMMR/MSI-H endometrial cancer.

Sarah Sammons, MD, discusses the evolving treatment landscape for metastatic HER2-postive breast cancer.

Richard Kim, MD, discusses the standard treatment approaches and unmet needs for patients with resectable colorectal cancer.

Razane El Hajj Chehade, MD, discusses a retrospective study of risk factors for irAEs in patients with metastatic renal cell carcinoma.

Odronextamab elicited deep, durable responses in heavily pretreated patients with relapsed/refractory follicular lymphoma.

Tycel Phillips, MD, expands on the treatment paradigm for patients with mantle cell lymphoma, highlighting recent data read-outs and FDA approvals/withdrawals

Mikkael A. Sekeres, MD, discusses the FDA approval of imetelstat for patients with low- to intermediate-1–risk MDS, highlighting data from a subanalysis.

KT-333 was well tolerated in relapsed/refractory hematologic and solid tumor cancers, including cutaneous T-cell lymphoma and peripheral T-cell lymphoma.

Dostarlimab plus chemotherapy demonstrated a meaningful overall survival improvement in primary endometrial cancer, regardless of mismatch repair status.

The FDA has granted fast track designation to Radspherin for the treatment of patients with peritoneal metastases from ovarian cancer.

IBI343 was well tolerated and demonstrated signs of efficacy in patients with CLDN18.2-positive advanced gastric/GEJ adenocarcinoma.

Durvalumab plus chemotherapy sustained an overall survival benefit vs chemotherapy alone in locally advanced or metastatic biliary tract cancer.

Kevin Kalinsky, MD, MS, discusses the outcomes of the postMONARCH study in patients with HR+/HER2– breast cancer following disease progression.

MPO may be a predictive biomarker for survival for treatment with CM24, nivolumab, and chemotherapy in second-line pancreatic ductal adenocarcinoma.

Lutetium Lu 177 dotatate with octreotide led to a clinical benefit in PFS and ORR regardless of tumor grade or primary origin in advanced grade 2 and grade 3 GEP-NETs.

The Japanese PMDA has approved first-line osimertinib plus chemotherapy for EGFR-mutated advanced non–small cell lung cancer.

Perioperative durvalumab demonstrated a statistically significant improvement in EFS and OS in muscle-invasive bladder cancer.

Sid Devarakonda, MD, details the role of surgery for patients with non–small cell lung cancer and approaches for treating patients with metastatic disease.

The EMA has validated an extension application for the subcutaneous formulation of nivolumab in adult patients with solid tumor indications.

Durvalumab/chemotherapy/bevacizumab, then durvalumab/bevacizumab/olaparib maintenance, sustained a PFS benefit in BRCA-unmutated advanced ovarian cancer.

DESTINY-Breast03 and DESTINY-Breast06 showed that T-DXd is a beneficial treatment approach in HER2-positive, -low, and -ultralow metastatic breast cancer.

Liso-cel demonstrated clinically meaningful activity regardless of the number of previous lines of systemic therapy or response to prior BTK inhibitors in MCL.

Frontline zanubrutinib/rituximab induction followed by short-course chemotherapy yielded efficacy in mantle cell lymphoma.

Sid Devarakonda, MD, details how new treatment strategies in the neoadjuvant and adjuvant settings are being implemented in the non–small cell lung cancer arena.

Eric Vallieres, MD, FRCSC, discussed recent advancements in surgical oncology regarding the treatment of patients with non–small cell lung cancer (NSCLC)